Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Bo Liu, University of Wisconsin-Madison, United States

*CORRESPONDENCE Li-Long Pan Ilpan@jiangnan.edu.cn Jia Sun jiasun@jiangnan.edu.cn Xun Sun sunxunf@shmu.edu.cn

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 05 July 2022 ACCEPTED 18 July 2022 PUBLISHED 05 August 2022

CITATION

Yuan B, Liu H, Dong X, Pan X, Sun X, Sun J and Pan L-L (2022) Corrigendum: A novel resveratrol analog upregulates SIRT1 expression and ameliorates neointima formation. *Front. Cardiovasc. Med.* 9:986353. doi: 10.3389/fcvm.2022.986353

COPYRIGHT

© 2022 Yuan, Liu, Dong, Pan, Sun, Sun and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC, BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: A novel resveratrol analog upregulates SIRT1 expression and ameliorates neointima formation

Baohui Yuan^{1,2†}, He Liu^{1,2†}, Xiaoliang Dong¹, Xiaohua Pan^{1,2}, Xun Sun^{3*}, Jia Sun^{1,2*} and Li-Long Pan^{1*}

¹Wuxi School of Medicine and School of Food Science and Technology, Jiangnan University, Wuxi, China, ²State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China, ³School of Pharmacy, Fudan University, Shanghai, China

KEYWORDS

(*R*)-TML104, neointima formation, nicotinamide adenine dinucleotide phosphate oxidase 4, nuclear factor- κ B, vascular smooth muscle cells, reactive oxygen species, SIRT1

A corrigendum on

A novel resveratrol analog upregulates SIRT1 expression and ameliorates neointima formation

by Yuan, B., Liu, H., Dong, X., Pan, X., Sun, X., Sun, J., and Pan, L.-L. (2021). Front. Cardiovasc. Med. 8:756098. doi: 10.3389/fcvm.2021.756098

In the published article, there was an error in Figures 1, 2 as published. Due to our mistake in combining images, two graphs in Figures 1B, 2D were misused. The corrected Figures 1, 2 appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.





(*R*)-TML104 inhibits PDGF-BB-induced VSMC phenotypic transformation *in vitro*. (**A**) VSMC were pretreated with (*R*)-TML104 for 4 h and then stimulated with PDGF-BB (20 ng/mL) for 24 h. The protein levels of α -SMA, PCNA, and cyclin D1 were determined by western blotting. (**B**) The protein levels of α -SMA, PCNA, and cyclin D1 were determined by western blotting. (**C**) DNA synthesis in VSMC was determined with an EdU incorporation assay. Blue fluorescence (Hoechst 33342) showed cell nuclei and green fluorescence (EdU) stands for cells with DNA synthesis. (**D**) Transwell assay was performed to determine the migration of VSMC. Scale bar: 50 μ m, Data shown are means \pm S.D (n = 6). *p < 0.05, **p < 0.01, **p < 0.001.